Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Summary
Postoperative nausea and vomiting (PONV) are a frequent and debilitating complications after surgery, affecting up to 80% of patients at high risk in the absence of prophylaxis. Despite the rigorous application of the recommendations from the American Society of Anesthesiologists (ASA) at CHUM, a recent local study reveals a prevalence of 25% PONV at home after outpatient surgery. However, the therapeutic options at home remain limited. This study aims to evaluate if the addition of 40 mg aprepitant to a multimodal strategy for preventing PONV improves clinical outcomes in high-risk patients undergoing outpatient surgery.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2026-02-27
Completion Date
2027-01-01
Last Updated
2026-03-03
Healthy Volunteers
No
Interventions
Aprepitant 40mg
Just before the patient is taken to the operating room, a single oral capsule of 40 mg of aprepitant will be given to the participant to evaluate the effectiveness of 40 mg of aprepitant in preventing postoperative nausea and vomiting (PONV) in outpatient surgery. The protocol was chosen to determine whether adding aprepitant to a standard multimodal strategy provides a clinically measurable benefit compared to placebo.
Placebo
Just before the patient is taken to the operating room, a single oral capsule of 40 mg of placebo will be given to the participant.
Locations (1)
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada